- Zoom's pre-market shares rose 7.49% after exceeding Q1 earnings expectations with a 7.2% year-on-year revenue increase, reaching $755.7 million.
- The company raised its full-year revenue and earnings guidance, projecting $5.08 billion to $5.09 billion in revenue and an adjusted EPS of $5.96 to $6.00.
- Akari Therapeutics surged 82.88% pre-market following news of a $5 million private placement and a 1-for-40 reverse stock split, enhancing investor interest and financial stability.
